Lucas de Breed is currently Director at Inkef Capital, where he joined in 2013. He brings over a decade of international experience in all phases of drug development, from pre-clinical stage start-ups to brand strategy and life cycle management for Top 10 Large Pharma. In his previous role at Deallus Consulting, he was responsible for their global oncology business and founded/managed the firm’s New York City office. Lucas holds a Ph.D. from University College London for research conducted at the LRI (now Francis Crick Institute), and an MBA from Stanford University. He has also co-authored several scientific papers.

Robert Jan Galema is a multi-lingual senior executive and investment professional with over 20 years of experience in global technology environments and a proven record of accomplishment. He has held senior executive positions at Philips and Electrolux as well as founded a number of companies. He has also held supervisory board and investment management positions. Robert Jan received a Master’s in Business Economics from the Erasmus University Rotterdam and followed an Executive MBA program at Duke University.

Janneke van Dongen joined INKEF January 1st 2016 as office manager. Over the past 13 years she has worked in an international environment as executive assistant for senior executive management, office management and project management. She particularly loves the innovation and startup environment and is very happy to be part of it once more.

Rianne joined Inkef in 2017 and is involved in sourcing and evaluating investment opportunities, and supporting portfolio companies in the healthcare team. Rianne joins Inkef from the academic community where she was a medical biologist in regenerative medicine. She obtained her PhD at Leiden University while performing part of her activities at biotech company Galapagos. Winning a grant facilitated her to take a position as postdoctoral fellow at the Kovler Diabetes Center at the University of Chicago. Next to performing her research, she became a fellow at the university’s Tech Transfer Office which has sparked her interest in the early stages of life sciences ventures.

Corné joined INKEF May 1, 2015 and focuses on early stage investing in the areas of enterprise SaaS & financial technology. He has 7 years of investment experience in technology. Prior to INKEF, Corné was a VP at HPE Growth Capital, a late stage growth fund where he looked at both B2B as well as B2C business models in the areas of fintech, applied materials and enterprise software. Before joining HPE, Corné worked in the London based Technology Coverage teams of Merrill Lynch and Credit Suisse First Boston, both in London where he executed several M&A transactions and IPOs. He holds a BSc in Finance from Reims Management School and a MSc. degree in Financial Management from the Nyenrode, Netherlands. When not working with start-up companies you might find Corné on the beach playing beach volleyball (though he admits there are better countries for this particular pastime), in the kitchen cooking, spending time with his family or reading up on technology trends. Prior to his career in technology he actually worked as a roady for several years, but that’s a different story.

Wolfgang Noeldeke became INKEF’s CFO in April 2017. He spent 20 years of his professional career in various roles in Venture Capital. Wolfgang started as an auditor and consultant of BDO, focusing on companies in the German Start Up and Venture Capital marketplace. From 2001 he worked for the British Private Equity company 3i as fund manager and later Financial Director of the German business unit. This role involved managing several Venture Capital funds in Germany and The Netherlands. In 2007 Wolfgang moved to Amsterdam to join Aescap Venture as CFO. Wolfgang holds a master of economy of the Technische Universitaet Berlin.

Fiona joined Inkef Capital as a Director in 2017 and brings over 20 years of experience in the Life Sciences and Healthcare industry, primarily in the founding and financing of early stage life science companies. Before joining Inkef, Fiona was an Associate at Advent Life Sciences. During her time at Advent, she co-founded Boston-based Arrakis Therapeutics, where she led Operations during the company’s Seed phase. Previously, Fiona spent 5 years as a Business Development Manager in the Technology Transfer Division of the Wellcome Trust, where she evaluated early stage product development opportunities and investments for Translational Funding, and established and ran the £45M “R&D for Affordable Healthcare” fund supporting technology development opportunities in India. Fiona has over 10 years of operational biotech experience and held senior roles as Head of Strategic Business and Product Development at RepRegen(tm) Ltd and Head of R&D at Gendel Ltd, and scientific roles at Phaeton Ltd and Valentis Inc. She was also an Advisor to Tiber Creek Partners, a US-based boutique consultancy advising life science companies of opportunities in sourcing non-dilutive capital. Fiona is a Pharmacist by training and has a PhD in drug delivery from Nottingham University.

Paolo McCarty joined the tech team in 2017 and is responsible for sourcing new deals, due diligence, and supporting INKEF’s portfolio companies. Paolo joins us from the San Francisco Bay Area where he did early-stage tech investing at Signia Venture Partners, business development at a database scaleup, and consulted for early-stage startups. He holds a degree from Stanford University in Management Science & Engineering. Outside of work, Paolo enjoys water polo, traveling around Europe, and attempting to cook edible food.

Mirella Tempelaars has been INKEF’s Operations Manager from Day 1, and has a comprehensive grasp of all our administration, marketing and HR. Previously, Mirella was a partner at Praktisch Werkt, where she provided vital back-office support to young start-ups. Mirella understands the organizational dynamics of all INKEF’s partners. Mirella has also held various operational positions at companies like Lextone and FundPartners, an investment arm started by NIB Capital.

Thijs Cohen Tervaert joined INKEF in September 2016. He is involved in deal origination, the assessment of investment cases and portfolio management. Prior to INKEF, Thijs was a strategy consultant at the Boston Consulting Group with a focus on health care and technology. He worked on projects for pharmaceutical companies, hospitals and insurers. During a one year secondment, Thijs helped to establish the Amsterdam Health and Technology Institute in 2014. Thijs is a medical doctor and graduated at Leiden University. He has also co-authored several scientific papers.

Kyang joined INKEF in November 2016. He has more than 10 years of experience in technology investing, across fintech, online marketplaces, enterprise software and manufacturing technology. Prior to INKEF, Kyang was responsible for M&A at Naspers’ fintech segment, which brought him to developing economies in 4 continents. At Naspers, he was instrumental in building a portfolio of fintech holdings and led one of the largest acquisitions in the payments space in Asia. Before Naspers, he was a VP at HPE Growth Capital, a growth-stage investment firm, where he drove the execution of several investments and was deeply involved in hands-on portfolio management. Kyang started his career as an investment banker in London (M&A) and Hong Kong (Principal Investments). He holds a Msc. degree in Financial Economics from the Vrije Universiteit Amsterdam. Outside of work, Kyang enjoys playing tennis and golf as well as travelling to exotic destinations with his wife and two boys.

Michael Stam became INKEF’s Chief Executive Officer in August 2012. As a chair member of our Investment Committee and representative of our founding partner ABP, Michael has been closely associated with INKEF since its inception in 2010. Previously, Michael managed APG’s Listed Equity Platform, focusing on selecting and monitoring external asset managers. Michael received a Bachelor’s degree in Law from the University of Leiden, an MBA from Delft University and a Master’s in Real Estate from the Amsterdam School of Real Estate.

Jan Keltjens joined INKEF in September 2015. Jan has extensive experience in the health care sector. He most recently served as chief executive officer of Sapiens Steering Brain Stimulation (acquired by Medtronic in August 2014). Before that he previously was the chairman and chief executive officer of Endosense SA (acquired by St Jude Medical in August 2013), executive chairman of Surpass Medical ltd. (acquired by Stryker Corporation late 2012), as well as president and chief executive officer of AngioDynamics Inc. (ANGO, 2009 – 2011) and CryoCath Technologies Inc. (TSX; CYT, 2007- until its acquisition by Medtronic in 2009). From 2000 to 2007, he served as Worldwide General Manager of Cordis Neurovascular, a Johnson & Johnson company. Jan currently holds a number of non-executive Board roles, including Chairman of the Board of JenaValve Technologies.

Patrick Vink joined INKEF in September 2016. He has more than 30 years experience in the life sciences industry in regional and global roles. Most recently he was Chief Operating Officer of Cubist Inc until the acquisition by MSD in 2015 . Prior to joining Cubist in 2012 he served as Senior Vice-President of global Institutional Business at Mylan since 2008. Earlier in his career he was head of the global business unit Biologics at Sandoz, Head of international operations at Biogen and head of worldwide Cardio-vascular and Thrombosis marketing at Sanafi-Synthelabo. Currently he is holding a number of non-executive director Board positions, including Chairman of Piqur AG, Acacia Pharma and NMD Pharma. Patrick graduated as a medical doctor from the University of Leiden and obtained his MBA at the University of Rochester and Rotterdam.

Martin C. Michel joined Inkef in May 2017. As physician board certified in Pharmacology and in Clinical Pharmacology, he has more than 30 years’ experience in academic and commercial drug discovery, translational pharmacology and development in Germany, the US and the Netherlands, including the discovery and clinical development of tamsulosin (Flomax®). From 2003-2011 he was Head of the Department of Pharmacology & Pharmacotherapy at the University of Amsterdam, from 2011-2016 Global Head of Product and Pipeline Scientific Support at Boehringer Ingelheim and since 2016 is Senior Partner at PAASP GmbH. His research focusses on urogenital and cardiovascular diseases, where he has published more than 500 scientific articles cited more than 21,000 times.

Adriaan Ligtenberg joined INKEF in May 2017. Currently, he is co-founder and Managing Partner at SparkHealth B.V. and is a Managing Director at Health2047, the innovation studio of the AMA (American Medical Association). He is a proven Silicon Valley executive with a track record in founding, building and exiting breakthrough technology-based companies. During his tenure at Bell Labs he worked on JPEG and MPEG compression standards and lectured in computer architecture at Princeton University. Adriaan went on to found Bay Area successes including C-cube and Storm Technology, and subsequently joined Cadence Design for a turn around as Sr VP WW Services. He was CEO of SpinCircuit, a joint venture between Cadence and FLEX, founded and chaired BMEYE BV, a cardiovascular medical device monitoring business, sold to Edwards Life Science. In 2015, he founded AllMobile, a seed-stage investment fund focusing on startups in the mobile, data and AI fields. Adriaan sits on the boards of multiple technology companies both in the Netherlands and in the United States. He holds several patents and received his PhD in Computer Science from École Polytechnique Fédérale de Lausanne.

Lex H.T. Van der Ploeg is CSO for Rhythm pharmaceuticals and functions as a member of the board of Directors for Retrotope Inc., and as an advisor to DeuteRx, LLC. Lex is a member of the SAB for Excellentia Global partners and an Advisor to Inkef Capital.  Lex functions as Managing Director for VDP, LLC, an independent consulting agency focused on guiding Research and Development for the Biotechnology and Pharmaceutical Industries and private investors. At VDP, LLC, Lex focuses on supporting R&D initiatives from a strategic and tactical perspective, as an integrated member of Management and R&D teams.

Lex’s expertise includes development of Diagnostics and Therapeutics including Cancer, Neurodegenerative disorders, Metabolic disorders and Infectious diseases. Prior to starting VDP, LLC Lex was the Sr. Vice President of Integrative Medicine and Translational Science at Abraxis/Celgene. Previously, Dr. Van der Ploeg held the position of, Vice president, Basic Research, and site head at Merck Research Laboratories Boston focused on oncology and neurodegenerative disease. Prior to starting Merck Research Laboratories Boston in December 2003, Dr. Van der Ploeg held diverse functions at Merck Research Laboratories including site head MRL San Diego and Head Obesity research for Merck Rahway and Banyu, Japan. At Merck, Lex held leadership roles in obesity and metabolism, oncology, neurodegenerative disease research and diagnostics.

Dr. Van der Ploeg received his M.S. degree (Summa Cum Laude) in Biochemistry in 1980 from the University of Amsterdam and his Ph.D. in Biochemistry/Enzymology/Genetics in 1984 from the University of Amsterdam/Netherlands Cancer Research Center. Following receipt of his Ph.D. Dr Van der Ploeg joined the faculty of the Dept of Genetics and Development of Columbia University, as an assistant Professor and received tenure at Columbia University in 1987. Dr Van der Ploeg held an adjunct faculty position at the Dept of Genetics and Development of Columbia University from 1992 through 2009. Dr. Van der Ploeg received numerous awards and grants for his research and has broadly published on his research in peer reviewed journals. He is an inventor on over 50 patents and patent applications.

Micha “mies” Hernandez van Leuffen joined Inkef in October of 2018 and specializes in developer tools, cloud infrastructure and enterprise SaaS. He currently is Vice President of Software Development at Oracle. Before joining Oracle he was the founder and CEO of Wercker, a container native continuous deployment platform with offices in Amsterdam, San Francisco and London. Wercker was acquired by Oracle in May of 2017. Mies wrote his Master’s thesis on autonomous resource provisioning at the University of San Francisco and has both a Master’s in Business Administration as well as Computer Science from the Vrije Universiteit in Amsterdam. In his spare time he is an angel investor and enjoys advising other startups.